The new UK–Switzerland Free Trade Agreement (FTA) is set to create exciting opportunities for the life sciences sector.
The modernised FTA represents a significant step forward for businesses operating across the UK and Switzerland, particularly in life sciences, biotech and pharmaceuticals.
At CK QLS, we see three key ways this agreement could reshape the talent landscape:
Easier access to specialist talent
Improved mobility provisions will make it easier for businesses to deploy specialists across both countries for projects, leadership appointments, technical expertise and business-critical initiatives. This is especially valuable for organisations operating across clinical development, regulatory affairs, commercial and market access functions.
Greater confidence to invest and grow
By providing a more stable framework for cross-border trade and investment, the agreement gives organisations the confidence to expand operations, launch new projects and build commercial teams to support continued growth in both markets.
Accelerating innovation in life sciences
With stronger collaboration around innovation, intellectual property, digital trade and research, we expect to see increased partnerships across biotech, pharma and medtech. As these collaborations grow, so too will the demand for experienced scientific, regulatory, quality, clinical and commercial professionals.
At CK QLS, we help life sciences organisations across Switzerland and the UK secure the specialist talent needed to support growth—whether that’s bringing UK expertise into Switzerland, helping Swiss companies expand into the UK, or building international project teams.
If you’re considering how the new UK–Swiss FTA could support your growth plans, we’d be delighted to discuss how CK QLS can help you attract the talent to make those ambitions a reality.
